Lenacapavir,marketed as Yaztojo,is a novel injectable drug administered every six months for HIV prevention,offering a more convenient choice to daily oral medications.

How does Lenacapavir work to prevent HIV?

lenacapavir belongs to a new class of antiviral medications that inhibit HIV's ability to infect immune cells and replicate, providing long-lasting protection against the virus.

What are the advantages of Lenacapavir over oral HIV prevention drugs?

Lenacapavir's primary advantage is its less frequent dosing schedule (every six months), which can improve adherence and convenience compared to daily oral medications. this is especially beneficial for individuals who struggle with consistent daily pill-taking.

Were is Lenacapavir available?

Following FDA approval, Lenacapavir is expected to become available in the United States. check with your healthcare provider for availability in your region.

“`html

FDA approves Injectable HIV Prevention Drug, Offering New hope

Q: How effective is Lenacapavir in preventing HIV?

Clinical trials have demonstrated that Lenacapavir is highly effective in preventing HIV transmission, with studies showing a significant reduction in infection rates compared to daily oral prep options.

Q: Is Lenacapavir approved for HIV treatment as well as prevention?

Yes, Lenacapavir was initially approved in 2022 for use in combination with other drugs to treat HIV in adults with multi-drug resistant strains of the virus. Now it is indeed also approved for prevention.

In a landmark decision that could reshape the landscape of HIV prevention, the U.S. Food and Drug Management (FDA) has approved Lenacapavir (YenacAPIVIR), a long-acting injectable drug administered every six months [[1]]. This approval marks a significant advancement over existing daily oral medications for pre-exposure prophylaxis (PrEP).

A New Era in HIV Prevention

Lenacapavir, also known as Yaztojo (scientific name Linacapavir), represents a paradigm shift in HIV prevention strategies. Unlike daily pills, this injectable medication offers a more convenient and perhaps more effective approach, particularly for individuals who may struggle with adherence to daily regimens. Clinical trials have demonstrated remarkable success, with the drug nearly eliminating virus spread among participants receiving injections every six months.

Did You Know? In 2022, approximately 1.2 million people in the United States had HIV, and about 13% of them didn

Blaces of the virus are highly resistant to the virus

AIDS Treatment Breakthrough: FDA Approves Injectable Therapy

FDA approves Injectable HIV Prevention Drug, Offering New hope

A New Era in HIV Prevention